Unknown

Dataset Information

0

Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.


ABSTRACT:

Background

Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment.

Methods

Children with HIV/tuberculosis coinfection weighing 3.0 to 19.9 kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment.

Results

Of 20 children enrolled; 15, 1-7 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir/ritonavir co-administered with rifampicin (n = 15; area under the curve0-24 55.32 mg/h/L [0.30-398.7 mg/h/L]; Cmax 3.04 mg/L [0.03-18.6 mg/L]; C8hr 0.90 mg/L [0.01-13.7 mg/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve24 121.63 mg/h/L [2.56-487.3 mg/h/L]; Cmax 9.45 mg/L [0.39-26.4 mg/L]; C12hr 3.03 mg/L [0.01-17.7 mg/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations ≥1mg/L.

Conclusions

Modified 8-hourly dosing of lopinavir/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation.

SUBMITTER: Chabala C 

PROVIDER: S-EPMC10501348 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.

Chabala Chishala C   Turkova Anna A   Kapasa Monica M   LeBeau Kristen K   Tembo Chimuka H CH   Zimba Kevin K   Weisner Lubbe L   Zyambo Khozya K   Choo Louise L   Chungu Chalilwe C   Lungu Joyce J   Mulenga Veronica V   Crook Angela A   Gibb Diana D   McIlleron Helen H  

The Pediatric infectious disease journal 20230720 10


<h4>Background</h4>Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of  ...[more]

Similar Datasets

| S-EPMC6640304 | biostudies-literature
| S-EPMC10069754 | biostudies-literature
| S-EPMC8366816 | biostudies-literature
| S-EPMC4267507 | biostudies-literature
| S-EPMC7179606 | biostudies-literature
| S-EPMC4997846 | biostudies-literature
| S-EPMC3993270 | biostudies-literature
| S-EPMC5762400 | biostudies-literature
| S-EPMC6783589 | biostudies-literature
| S-EPMC10720412 | biostudies-literature